Unmet Need & Semprus BioSciences' Solution

The Need for Improved Technology

Established medical technology manufacturers widely use outdated technologies (such as silver and heparin coatings) to prevent complications associated with implanted devices. These technologies suffer from numerous drawbacks, which limit their ability to provide the multi-faceted long term protection required for modern medical devices:

• Limited duration of effectiveness, as the added agents are either depleted or degraded over time.
• Limited efficacy, due to their narrow mechanism of action.
• Lack of targeting the initial “adhesion” step in biofilm formation and thrombosis, which is often the origin of the problem.
• Absence of simultaneous anti-colonization and anti-thrombogenic activity to prevent these highly interrelated phenomena.
• Limited spectrum of activity against diverse pathogens.
• Minimal “anti-biofilm” activity, which is a primary contributor to device infections.
• Potential toxicity and drug resistance.

The Market Solution

With its world-class team of scientists, Semprus Biosciences is developing Semprus Surfaces™, its next-generation biofunctional surface platform, which is focused on achieving clinical benefits far exceeding those of silver, heparin, and antibiotic coatings. The company’s innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology while vastly improving patient outcomes and reducing health care costs.

Our current focus is to enable the first dual-functional, permanent, anti-colonization and anti-thrombogenic vascular access catheter. This proprietary technology platform may also facilitate novel therapies previously constrained by infection or thrombus – enabling Semprus Biosciences to independently deliver groundbreaking new products for a variety of indications and health care markets.